Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro

14 Dec 2017

Abstract excerpt

// Xiuli Feng 1, 2, * , Yan Zhang 1, 3, * , Tao Li 1 and Yu Li 1 1 Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China 2 Department of Respiratory Medicine, People’s Hospital of Qingzhou, Weifang, Shandong 262500, China 3 The Fourth People’s Hospital of Jinan, Jinan, Shandong 250031, China * These authors have contributed equally to this work Correspondence to:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastric Cancer Management and Outcomes
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29371987
DOI: 10.18632/oncotarget.23224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitroPMID 29371987Read ↗

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.Semantic proximity Read ↗

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.Semantic proximity Read ↗

Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma.Semantic proximity Read ↗

[Effects of EGFR-TKIs on sequential pemetrexed for advanced pulmonary adenocarcinoma].Semantic proximity Read ↗

Efficacy of icotinib in advanced lung squamous cell carcinoma.Semantic proximity Read ↗

Cell death-based treatment of lung adenocarcinoma.Semantic proximity Read ↗

Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)Semantic proximity Read ↗

Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidenceSemantic proximity Read ↗

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma.Semantic proximity Read ↗

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingSemantic proximity Read ↗

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.Semantic proximity Read ↗

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.